Key facts
- It has raised $180K; the latest was Seed Round ($30K) in Feb 2026.
- Notable investors include Link Parks.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Compvide
- ·The full record, as it builds
Funding rounds
No funding rounds for Compvide are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Compvide
Provider of research reagents and assay services designed to accelerate complement system studies. The company offers next-generation activation/inhibition assay buffers, premium serum and plasma reagents, and bespoke pathway-specific assays, enabling immunology researchers and biotech developers to advance complement system understanding with compliant tools.
- Sector
- Healthcare
- HQ
- Renton, WA, United States
- Founded
- 2024
- Website
- compvide.com/
- Ownership
- Privately Held (backing)
Compvide doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Compvide shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Compvide in its N-PORT filings yet. We sweep new filings monthly.